The ongoing dedicated ophthalmic trial named as FOCUS study, which aims to evaluate semaglutides long-term effects on diabetic retinopathy, is now ongoing and could contribute to a comprehensive understanding of the true risk-benefit profile of these agents in patients with or at risk for diabetic retinopathy (NCT03811561) [104]
Although several therapeutic strategies have attempted to reverse this metabolic imbalance (57), there is still no approved treatment regimen to date
The company still carries 4 flagged risks, including dividend coverage concerns, share price volatility and a high level of debt.
Splitting into twice-daily injections is reasonable at higher daily totals (e.g., 250 mcg AM + 250 mcg PM at a 500 mcg/day total)
Our health is much the same
Anxiolytic effects of a galacto-oligosaccharides prebiotic in healthy females (1825 years) with corresponding changes in gut bacterial composition